Xeris Biopharma (NASDAQ:XERS) Insider Sells $722,700.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin Mcculloch sold 90,000 shares of Xeris Biopharma stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $8.03, for a total transaction of $722,700.00. Following the transaction, the insider owned 1,691,126 shares of the company’s stock, valued at approximately $13,579,741.78. The trade was a 5.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Price Performance

XERS stock opened at $8.28 on Friday. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50. The company’s 50 day simple moving average is $6.61 and its 200-day simple moving average is $6.63. Xeris Biopharma Holdings, Inc. has a 12 month low of $4.62 and a 12 month high of $10.08. The firm has a market capitalization of $1.43 billion, a PE ratio of 138.00 and a beta of 0.62.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. The firm had revenue of $83.13 million during the quarter, compared to the consensus estimate of $79.83 million. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%. Equities analysts expect that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on XERS shares. Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $10.80.

Institutional Trading of Xeris Biopharma

Several hedge funds and other institutional investors have recently bought and sold shares of XERS. Royal Bank of Canada raised its holdings in Xeris Biopharma by 1,411.2% in the 1st quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock valued at $1,170,000 after acquiring an additional 198,984 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Xeris Biopharma by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock worth $461,000 after purchasing an additional 3,594 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Xeris Biopharma by 19.0% during the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock worth $12,726,000 after purchasing an additional 369,420 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after purchasing an additional 1,199,435 shares during the period. Finally, Caxton Associates LLP purchased a new stake in shares of Xeris Biopharma in the first quarter valued at $170,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.